Compare EEIQ & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEIQ | NXL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.5M |
| IPO Year | 2019 | 2022 |
| Metric | EEIQ | NXL |
|---|---|---|
| Price | $3.11 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.0K | ★ 19.7K |
| Earning Date | 06-25-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.15 | $0.22 |
| 52 Week High | $12.70 | $67.20 |
| Indicator | EEIQ | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 28.64 | 30.47 |
| Support Level | $2.85 | $1.31 |
| Resistance Level | $3.82 | $5.36 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.09 | 0.13 |
| Stochastic Oscillator | 20.15 | 10.00 |
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S, Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. The Company's revenue is derived from foreign education programs, university education programs and student accommodation services.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.